Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited .
Filed returns
302
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2020 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland. (Legislation) | 9 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Transport | Sustainable Mobility as core component of climate action solutions (Legislation) | 1 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Transport | Impact of Covid-19 on car rental industry and the Irish Tourism Sector as a whole (Legislation) | 16 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 16 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Arts | Covid-19 Recovery Plan for Irish Photographers and Videographers (Public policy or programme) | 22 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 5 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland and the role of sustainable mobility solutions in climate action solutions. (Legislation) | 6 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Transport | The impact of COVID-19 on the tourism sector in Ireland, and the specific impact it is having the Irish car rental industry (Legislation) | 20 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) | 10 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 8 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Housing | Share experience of co-living and demonstrate The Collective's vision for successful co-living Dublin (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland and the role of sustainable mobility solutions in climate action solutions. (Legislation) | 3 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Heritage | Drafting of secondary legislation to allow for the transposing of Article 19 of Commission Regulation No. 865/2006 of 4 May 2006 into Irish law. (Legislation) | 6 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Finance | Cost of Motor Insurance Policies in Ireland (Legislation) | 13 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Housing | Share experience of co-living and demonstrate The Collective's vision for successful co-living Dublin (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | Engaged Government Ministers on patient safety, STEM education and healthcare innovation (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Finance | Cost of Motor Insurance Policies in Ireland (Legislation) | 27 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Development and Zoning | Amendment of the Eastern & Midland Regional Assembly’s Regional Spatial Economic Strategy, changes to zoning law & to secure relevant zoning for residential development of Newlands site. (Zoning or development) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Heritage | Drafting of secondary legislation to allow for the transposing of Article 19 of Commission Regulation No. 865/2006 of 4 May 2006 into Irish law. (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Finance | Finance Bill 2018 (Legislation) | 4 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Finance | Finance Bill 2018 (Legislation) | 13 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Finance | Cost of Motor Insurance Policies in Ireland (Legislation) | 21 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Heritage | Amendment of secondary legislation governing the management of fauna trade permits under the Wildlife (Import and Export of Fauna and Flora) (Amendment) Regulations 2011 and the Convention on International Trade in… (Legislation) | 3 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2018 | Hanover Media Strategy Limited | Heritage | Amendment of secondary legislation governing the management of fauna trade permits under the Wildlife (Import and Export of Fauna and Flora) (Amendment) Regulations 2011 and the Convention on International Trade in… (Legislation) | 6 | On lobbying.ie |
| May–Aug 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 13 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndrome (Matters involving public funds) | 12 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Finance | Consumer Protection for SMEs (Legislation) | 7 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 12 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Telehealth policy in Ireland (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Funding of Mental Health Organisations (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Finance | Consumer Protection for SMEs (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 8 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) | 18 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) | 8 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Rare Disease Medicines (Public policy or programme) | 11 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Naltrexone for Opiate Addiction (Matters involving public funds) | 4 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Telehealth policy in Ireland (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Economic Development and Industry | Engagement in relation to Companies Act 2014 on behalf of Coalition for Irish International Companies (Legislation) | 8 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 110 | 36.4% | |
| Transport | 98 | 32.5% | |
| Economic Development and Industry | 27 | 8.9% | |
| Energy and Natural Resources | 16 | 5.3% | |
| Finance | 14 | 4.6% | |
| Children and Youth Affairs | 11 | 3.6% | |
| Sports and Recreation | 5 | 1.7% | |
| Environment | 4 | 1.3% | |
| Heritage | 4 | 1.3% | |
| Communications | 3 | 1.0% | |
| EU Affairs | 3 | 1.0% | |
| Housing | 2 | 0.7% | |
| Arts | 1 | 0.3% | |
| Development and Zoning | 1 | 0.3% | |
| Education and Training | 1 | 0.3% | |
| Taxation | 1 | 0.3% | |
| Trade | 1 | 0.3% |